Of the 16 IDH1-mutated patients without NPM1 mutation, eight patients with marrow blasts <5% had IDH1 LNA-qPCR MRD > 2 log reduction (Figure S4), four patients with refractory AML and marrow blasts >5% (ranged 9.7% to 59.3%) had IDH1 LNA-qPCR MRD ≤ 2 log reduction (Figure S5), and four patients with marrow blasts <5% had persistent IDH1 qPCR MRD ≤ 2 log reduction (Figure S3b). This evidence concerns the gene IDH1 and acute myeloid leukemia.